Can post-treatment free PSA ratio be used to predict adverse outcomes in recurrent prostate cancer?
Hanan GoldbergRachel GlicksmanDixon WoonAlly HoffmanHina ShaikhThenappan ChandrasekarZachary KlaassenChristopher J D WallisArdalan E AhmadNoelia Sanmamed-SalgadoXuanlu QuFabio Y MoraesEleftherios P DiamandisAlejandro BerlinNeil E FleshnerPublished in: BJU international (2020)
A post-treatment FPSAR of ≥0.10 is associated with more aggressive disease, suggesting a potentially novel role for this biomarker.